The Wichita Community Clinical Oncology Program (WCCOP), established and funded by the National Cancer Institute in 1983, continued in 1987 and 1990, is a city-wide cooperative program of the three major community hospitals and the majority of Wichita's oncologists. During the past four years, the WCCOP averaged 165 credits per year on treatment protocols and exceeded our goal of 150 credits each year. Additionally, we have achieved our goal of expanding our cancer control research program to equal stature with treatment. Indeed, in the fiscal year 1993-1994, our cancer control credits surpassed treatment with a 12-month accrual of 195 credits. The WCCOP plans an annual accrual of 150 credits on treatment protocols and 150 credits on cancer control protocols using the five research bases: the Southwest Oncology Group, M.D. Anderson Cancer Center, National Surgical Adjuvant Breast and Bowel Project, University of Rochester Cancer Center, and the Pediatric Oncology Group.
The specific aims of the WCCOP are: (1) to stimulate quality medical care through participation in protocol studies for cancer patients in Wichita and southern central Kansas - a patient population which would otherwise be unserved because its geographic location is remote from comprehensive cancer centers; (2) to increase accrual of patients on National Cancer Institute treatment protocols and thus reduce the time necessary to answer critical questions; (3) to strengthen and maintain cancer control effort of the WCCOP to equal that of cancer treatment. We will involve primary care physicians and other specialists along with oncologists in intervention cancer control research, including chemoprevention, early detection, patient management, rehabilitation and continuing care; and (4) to bring the benefits of clinical research to rural parts of Kansas by including six rural hospitals as Wichita CCOP affiliates. With our track record as a successful CCOP for 11 years, and over 3,000 new cancer patients each year, we have the necessary expertise and commitment to continue our successful therapeutic and cancer control research efforts.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA035431-15
Application #
2646443
Study Section
Special Emphasis Panel (SRC (16))
Project Start
1983-09-15
Project End
2000-05-31
Budget Start
1998-06-01
Budget End
1999-05-31
Support Year
15
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Via Christi Regional Medical Center
Department
Type
DUNS #
City
Wichita
State
KS
Country
United States
Zip Code
67214
Barton, Debra L; Sloan, Jeff A; Shuster, Lynne T et al. (2018) Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer 26:643-650
Cheng, Heather H; Plets, Melissa; Li, Hongli et al. (2018) Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. Prostate 78:121-127
Garg, Madhur K; Zhao, Fengmin; Sparano, Joseph A et al. (2017) Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205). J Clin Oncol 35:718-726
Agarwala, Sanjiv S; Lee, Sandra J; Yip, Waiki et al. (2017) Phase III Randomized Study of 4 Weeks of High-Dose Interferon-?-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Gro J Clin Oncol 35:885-892
Liu, Xiaonan; Li, Jing; Schild, Steven E et al. (2017) Statins and Metformin Use Is Associated with Lower PSA Levels in Prostate Cancer Patients Presenting for Radiation Therapy. J Cancer Ther 8:73-85
Hubbard, Joleen M; Mahoney, Michelle R; Loui, William S et al. (2017) Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance). Target Oncol 12:201-209
Sio, Terence T; Atherton, Pamela J; Birckhead, Brandon J et al. (2016) Repeated measures analyses of dermatitis symptom evolution in breast cancer patients receiving radiotherapy in a phase 3 randomized trial of mometasone furoate vs placebo (N06C4 [alliance]). Support Care Cancer 24:3847-55
Liu, Xiaonan; Li, Jing; Wu, Teresa et al. (2016) Patient Specific Characteristics Are an Important Factor That Determines the Risk of Acute Grade ? 2 Rectal Toxicity in Patients Treated for Prostate Cancer with IMRT and Daily Image Guidance Based on Implanted Gold Markers. OMICS J Radiol 5:
Pachman, Deirdre R; Qin, Rui; Seisler, Drew et al. (2016) Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505). Support Care Cancer 24:5059-5068
Ji, Yongli; Rankin, Cathryn; Grunberg, Steven et al. (2015) Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005. J Clin Oncol 33:4093-8

Showing the most recent 10 out of 307 publications